Safety, Tolerability and PK of AZD1152 in Patients with Relapsed Acute Myeloid Leukaemia (AML)

Exclusion Criteria

• - Administration of anticancer agents (other than hydroxyurea) within 2 weeks prior to first dose of study drug, and administration of hydroxyurea within 24 hours prior to first dose of study drug
• - Participation in any other trial with an investigational product within the previous 30 days.
• - Uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, cardiac arrhythmia or psychiatric illness/social situations